Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1790P - Single-cell ex vivo drug response testing platform on fluid samples from patients with solid tumors

Date

16 Sep 2021

Session

ePoster Display

Topics

Cancer Biology;  Translational Research;  Pathology/Molecular Biology

Tumour Site

Presenters

Lorenz Bankel

Citation

Annals of Oncology (2021) 32 (suppl_5): S1211-S1226. 10.1016/annonc/annonc716

Authors

L. Bankel1, R. Wegmann2, K.J. Dedes3, D. Franzen4, P.K. Bode5, M. Zoche5, F. Arnold5, H. Moch5, M.G. Manz1, C. Britschgi1, B. Snijder2

Author affiliations

  • 1 Department Of Medical Oncology And Hematology, Comprehensive Cancer Center Zurich, University Hospital Zurich, 8091 - Zürich/CH
  • 2 Institute Of Molecular Systems Biology, ETH Zurich, 8093 - Zurich/CH
  • 3 Department Of Gynecology, Comprehensive Cancer Center Zurich, University Hospital Zürich, 8091 - Zurich/CH
  • 4 Department Of Pulmonology, Comprehensive Cancer Center Zurich, University Hospital Zurich, 8091 - Zürich/CH
  • 5 Department Of Pathology And Molecular Pathology, Comprehensive Cancer Center Zurich, University of Zürich and University Hospital Zürich, 8091 - Zurich/CH

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1790P

Background

In patients with metastatic malignancies there is an urgent need for predictive biomarkers. Fluids containing tumor cells, like pleural effusion or ascites, are easily accessible and could potentially provide information on drug sensitivities ex vivo..

Methods

Image-based single-cell drug response testing (pharmacoscopy) on fluid samples containing malignant cells is used to assess drug response variability on an intra- and interpersonal level. A population of malignant and healthy cells is incubated with a drug panel for 24 hours. After staining with fluorescent antibodies, cells are imaged using automated microscopy. A convolutional neural network infers cell types (malignant vs normal) directly from single-cell images. Using bulk RNA sequencing and targeted next generation sequencing, transcriptomic and genomic data is correlated with the ex vivo drug responses. Eventually, data will be matched with clinical response.

Results

So far, the cohort includes 154 samples from 110 patients. 70% of patients had a sample with sufficient viability and cancer cell content permitting pharmacoscopy. In 19 patients, pharmacoscopy was repeated on specimens taken at different time points, for which we observed a high intra-individual reproducibility of the drug response profiles. Taken together, these results highlight the technical feasibility and robustness of pharmacoscopy on fluid biopsies. At this early stage of this study, we want to highlight one case of a patient with BRAF p.V600E mutated lung adenocarcinoma. Combined tyrosine kinase inhibition with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) was started and resulted in a partial response. In parallel, pharmacoscopy showed an ex vivo response to dabrafenib as the most effective drug.

At the meeting, updated results incorporating transcriptomic and genomic data in correlation with drug responses will be presented.

Conclusions

Pharmacoscopy on fluid samples is a feasible diagnostic tool to assess drug responses. Integration of drug response profiles and morphological profiles with molecular measurements including genomic and transcriptomic profiling will provide further insights into the molecular mechanisms underlying drug response variability.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

University Hospital Zurich.

Funding

European Research Council (ERC).

Disclosure

C. Britschgi: Financial Interests, Personal, Other: AstraZeneca; Financial Interests, Personal, Other: Pfizer; Financial Interests, Personal, Other: Roche; Financial Interests, Personal, Other: Takeda; Financial Interests, Personal, Other: Janssen-Cilag; Financial Interests, Personal, Other: Boeringer Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.